h2E2 Antibody and D1 Antagonist Combination for Cocaine Relapse

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There are no FDA-approved medications for treating cocaine use disorders, including addiction and relapse, and existing therapies are inadequate for addressing the neuromodulatory effects of cocaine, leading to increased risk of relapse and drug-seeking behavior.

Innovation Solution

A combination of a humanized 2E2 monoclonal antibody (h2E2) and a dopamine 1 receptor antagonist is administered to reduce the neuromodulatory effect of cocaine, targeting both the binding of cocaine in the bloodstream and the dopamine receptors in the brain to decrease drug-seeking behavior and relapse risk.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If no FDA-approved medications are used for treating cocaine use disorders, then treatment options remain limited and unproven, but the lack of effective pharmacological intervention leads to high relapse rates and continued drug-seeking behavior

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidtreatment options

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The treatment is divided into two distinct components: (1) h2E2 monoclonal antibody that binds cocaine in the bloodstream to prevent brain entry, and (2) dopamine 1 receptor antagonist that blocks cocaine's effects within the brain. This segmentation allows each component to target a specific mechanism, creating a comprehensive treatment approach that addresses both peripheral and central actions of cocaine.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention combines two pharmacologically distinct agents (monoclonal antibody and receptor antagonist) into a composite treatment regimen. This composite approach leverages the unique properties of each agent—the antibody's ability to sequestre cocaine peripherally and the antagonist's ability to block central dopamine receptors—thereby creating a synergistic effect that neither agent could achieve alone.

Inventive Principle:

Principle #40Composite materials

2Ease of operation

If existing therapies are used, then some treatment is provided, but they fail to adequately address the neuromodulatory effects of cocaine, resulting in insufficient reduction of relapse risk

Engineering Contradiction:

Improvetreatment availabilityVSAvoidrelapse prevention

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The h2E2 monoclonal antibody is administered to preemptively bind cocaine molecules in the bloodstream before they can cross the blood-brain barrier. This preliminary action prevents cocaine from reaching its target receptors in the brain, thereby blocking the neuromodulatory effects before they can initiate relapse or drug-seeking behavior.

Inventive Principle:

Principle #9Preliminary anti-action

Solution Approach 2:

The dopamine 1 receptor antagonist serves as an intermediary that blocks the interaction between cocaine and dopamine receptors in the brain. By occupying these receptors, the antagonist prevents cocaine from exerting its neuromodulatory effects, thereby reducing the reinforcing and compulsive aspects of cocaine use that lead to relapse.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Device complexity

If a single mechanism of action is targeted, then the treatment approach is simple, but it cannot sufficiently reduce both drug-seeking behavior and relapse risk

Engineering Contradiction:

Improvetreatment regimenVSAvoidbehavioral outcome

Core Design Contradiction:

Device complexityVSReliability

Solution Approach 1:

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention changes multiple pharmacological parameters simultaneously: (1) cocaine concentration in the brain is reduced by peripheral binding, and (2) receptor sensitivity is modified by antagonist blockade. By altering these parameters at different levels (peripheral and central), the treatment achieves a more robust and reliable reduction in drug-seeking behavior and relapse risk.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination of h2E2 and a dopamine 1 receptor antagonist effectively reduces the neuromodulatory effect of cocaine, decreasing the latency and duration of drug-seeking behavior, and raises the cocaine compulsion zone, thereby reducing the risk of relapse and drug-seeking in subjects.

Implementation Method 1

The h2E2 binds cocaine with 3.9 nM affinity and sequesters it from plasma

Methodology Applied

Scientific EffectAntibody binding: Absorption (physical)

Implementation Method 2

a dopamine 1 receptor antagonist which work together to reduce the neuromodulatory effect of cocaine

Methodology Applied

Scientific EffectReceptor antagonism: Absorption (physical)

Data Source

PatentUS20250340671A1Methods and pharmaceutical compositions for reducing the neuromodulatory effect of cocaine

Publication Date: 2025.11.06 UNIVERSITY OF CINCINNATI

AI summary

A method of reducing the risk of a cocaine-addicted subject relapsing in addiction is provided, the method including administering to the subject a combination of an effective amount of humanized 2E2 (h2E2) monoclonal antibody and an effective amount of a dopamine 1 receptor antagonist, such as SCH23390. Also provided are methods of reducing cocaine drug-seeking behavior, methods of reducing the neuromodulatory effect of cocaine on the brain of a subject, and a pharmaceutical composition including h2E2 monoclonal antibody, a dopamine 1 receptor antagonist, and a pharmaceutically-acceptable excipient.